Efficacy and safety of adalimumab for the Crohn’s disease: a systematic review and meta-analysis of published randomized placebo-controlled trials

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

(2013) Pieter Dewint et al.   GUT

Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study

(2013) Zhirong Zeng et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

(2011) Natalie A. Molodecky et al.   GASTROENTEROLOGY

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

(2011) Mamoru Watanabe et al.   Journal of Crohns & Colitis

Increasing Incidence of Inflammatory Bowel Disease Among Young Men in Korea Between 2003 and 2008

(2010) Dong Hyuk Shin et al.   DIGESTIVE DISEASES AND SCIENCES

The potential for disease modification in Crohn's disease

(2010) G. Van Assche et al.   Nature Reviews Gastroenterology & Hepatology

Adalimumab for the treatment of fistulas in patients with Crohn's disease

(2009) J-F Colombel et al.   GUT

Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease

(2009) Andrea Cassinotti et al.   INFLAMMATORY BOWEL DISEASES